表紙
市場調査レポート

水虫(足白癬):パイプライン製品の分析

Athlete's Foot (Tinea Pedis) - Pipeline Review, H1 2014

発行 Global Markets Direct 商品コード 213129
出版日 ページ情報 英文 41 Pages
即納可能
価格
本日の銀行送金レート: 1USD=101.39円で換算しております。
Back to Top
水虫(足白癬):パイプライン製品の分析 Athlete's Foot (Tinea Pedis) - Pipeline Review, H1 2014
出版日: 2014年04月30日 ページ情報: 英文 41 Pages
概要

水虫(足白癬)は足部で一般的に見られる感染症で、白癬菌という真菌により発症します。主な症状として、足裏の皮膚の乾燥化・剥離や、足部の臭気、足裏に生じる小さく痒い水疱などが挙げられます。主な治療法には抗真菌薬などがあります。

当レポートでは、世界各国での水虫(足白癬)治療用のパイプライン製品の開発状況について分析し、製品開発・上市の最新動向や、治験の各段階にある製品の一覧、主要企業のプロファイル、主な薬剤の概要、最新の業界動向などの情報をお届けします。

目次

イントロダクション

  • 分析範囲

水虫(足白癬)の概要

治療薬の開発

  • 水虫向けパイプライン製品:概要
  • 水虫向けパイプライン製品:比較分析

各企業で開発中の水虫治療薬

パイプライン製品の概略

  • 治験段階の製品
  • 初期段階の製品

水虫治療薬:開発中の製品の一覧(企業別)

水虫治療薬の開発に従事している企業

  • Actavis plc
  • Helix BioMedix, Inc.
  • Anacor Pharmaceuticals, Inc.
  • Viamet Pharmaceuticals, Inc.

水虫:治療薬の評価

  • 単剤治療薬の場合
  • 標的別
  • 作用機序別
  • 投与方法別
  • 分子の種類別

薬剤のプロファイル

  • アルバコナゾール
    • 製品概要
    • 機能メカニズム
    • 研究開発(R&D)の進展状況
  • VT-1161
  • AN-2718
  • HB-1275
  • クエン酸二水素銀

水虫治療薬:パイプライン製品の最新動向

水虫治療薬:開発が休止状態の製品

水虫関連製品の開発のマイルストーン

  • 注目すべき最新動向・プレスリリース(全3件)

付録

図表一覧

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC4899IDB

Global Markets Direct's, 'Athlete's Foot (Tinea Pedis) - Pipeline Review, H1 2014', provides an overview of the Athlete's Foot (Tinea Pedis)'s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Athlete's Foot (Tinea Pedis), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Athlete's Foot (Tinea Pedis) and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Athlete's Foot (Tinea Pedis)
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Athlete's Foot (Tinea Pedis) and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Athlete's Foot (Tinea Pedis) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Athlete's Foot (Tinea Pedis) pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products

Reasons to buy

  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Athlete's Foot (Tinea Pedis)
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Athlete's Foot (Tinea Pedis) pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Athlete's Foot (Tinea Pedis) Overview
  • Therapeutics Development
    • Pipeline Products for Athlete's Foot (Tinea Pedis) - Overview
    • Pipeline Products for Athlete's Foot (Tinea Pedis) - Comparative Analysis
  • Athlete's Foot (Tinea Pedis) - Therapeutics under Development by Companies
  • Athlete's Foot (Tinea Pedis) - Pipeline Products Glance
    • Clinical Stage Products
    • Early Stage Products
  • Athlete's Foot (Tinea Pedis) - Products under Development by Companies
  • Athlete's Foot (Tinea Pedis) - Companies Involved in Therapeutics Development
    • Actavis plc
    • Helix BioMedix, Inc.
    • Anacor Pharmaceuticals, Inc.
    • Viamet Pharmaceuticals, Inc.
  • Athlete's Foot (Tinea Pedis) - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • albaconazole - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • VT-1161 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • AN-2718 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • HB-1275 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • silver dihydrogen citrate - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Athlete's Foot (Tinea Pedis) - Recent Pipeline Updates
  • Athlete's Foot (Tinea Pedis) - Dormant Projects
  • Athlete's Foot (Tinea Pedis) - Product Development Milestones
    • Featured News & Press Releases
      • Mar 12, 2014: Viamet Reports Positive Interim Results of Phase 2 Interdigital Tinea Pedis Study of VT-1161
      • Nov 15, 2013: Valeant Pharmaceuticals Announces U.S. Approval Of Luzu Cream, 1%
      • Sep 12, 2012: Topica Pharma Presents Findings From Phase I/IIa Trial Of Luliconazole Solution In Onychomycosis At ICAAC 2012
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Athlete's Foot (Tinea Pedis), H1 2014
  • Number of Products under Development for Athlete's Foot (Tinea Pedis) - Comparative Analysis, H1 2014
  • Number of Products under Development by Companies, H1 2014
  • Comparative Analysis by Clinical Stage Development, H1 2014
  • Comparative Analysis by Early Stage Development, H1 2014
  • Products under Development by Companies, H1 2014
  • Athlete's Foot (Tinea Pedis) - Pipeline by Actavis plc, H1 2014
  • Athlete's Foot (Tinea Pedis) - Pipeline by Helix BioMedix, Inc., H1 2014
  • Athlete's Foot (Tinea Pedis) - Pipeline by Anacor Pharmaceuticals, Inc., H1 2014
  • Athlete's Foot (Tinea Pedis) - Pipeline by Viamet Pharmaceuticals, Inc., H1 2014
  • Assessment by Monotherapy Products, H1 2014
  • Number of Products by Stage and Target, H1 2014
  • Number of Products by Stage and Mechanism of Action, H1 2014
  • Number of Products by Stage and Route of Administration, H1 2014
  • Number of Products by Stage and Molecule Type, H1 2014
  • Athlete's Foot (Tinea Pedis) Therapeutics - Recent Pipeline Updates, H1 2014
  • Athlete's Foot (Tinea Pedis) - Dormant Projects, H1 2014

List of Figures

  • Number of Products under Development for Athlete's Foot (Tinea Pedis), H1 2014
  • Number of Products under Development for Athlete's Foot (Tinea Pedis) - Comparative Analysis, H1 2014
  • Number of Products under Development by Companies, H1 2014
  • Comparative Analysis by Clinical Stage Development, H1 2014
  • Assessment by Monotherapy Products, H1 2014
  • Number of Products by Top 10 Target, H1 2014
  • Number of Products by Stage and Top 10 Target, H1 2014
  • Number of Products by Top 10 Mechanism of Action, H1 2014
  • Number of Products by Stage and Top 10 Mechanism of Action, H1 2014
  • Number of Products by Top 10 Route of Administration, H1 2014
  • Number of Products by Stage and Top 10 Route of Administration, H1 2014
  • Number of Products by Top 10 Molecule Type, H1 2014
  • Number of Products by Stage and Top 10 Molecule Type, H1 2014
Back to Top